Christian P. Larsen, MD, DPhil

Chief Scientific Officer, Woodruff Health Sciences and Emory Healthcare
Christian P. Larsen

Additional Titles

Executive Director 
Emory Transplant Center

Carlos and Marguerite Mason Professor of Transplantation and Surgery
Emory University

Biography

Christian P. Larsen, MD, DPhil, is the Carlos and Marguerite Mason Professor of Transplantation and Surgery at Emory University and chief scientific officer of Woodruff Health Sciences and Emory Healthcare. He also serves as the executive director of Emory Transplant Center, building and directing one of the leading research and clinical transplantation programs in the nation. To date, the center has performed more than 14,000 organ transplants, with more than 520 transplants performed thus far in 2026.

Larsen is the recipient of the 2026 American College of Surgeons Jacobson Innovation Award. The award honors living surgeons who have innovated a new development or technique in any field of surgery. The award is made possible through a gift from Julius H. Jacobson II, MD, FACS, a vascular surgeon known for pioneering work in microsurgery, and his wife.

Larsen, an internationally recognized leader in transplant surgery and immunology, joined the Emory medical faculty in 1991 and was appointed Chair of Surgery in 2009. His clinical practice focused on kidney, pancreas, and islet transplantation at Emory University Hospital and Children's Healthcare of Atlanta. He is also an affiliate scientist at Yerkes National Primate Research Center.

He became founding director of the Emory Transplant Center (ETC) in 2001, building and directing one of the foremost research and clinical transplantation programs in the world. The center is most noteworthy for its leadership in the early integration of clinical care and research. In 2003, he and his team performed the first islet transplant in Georgia and have continued to be leaders in this innovative field of transplant.

Under Larsen, the ETC has been a national pacesetter in establishing new standards to ensure reliable, patient-centered care, focusing on multidisciplinary care a full decade before its recognition as an essential attribute in patient care. In addition, the ETC has been one of the nation's leading centers for National Institutes of Health research funding in basic immunology, in translational studies in non-human primates, and in large, multi-center clinical trials.

Together with long-time collaborator Thomas Pearson, MD, DPhil, Larsen has played a pivotal role in developing a new class of immunosuppressive drugs, the co-stimulation blockers. Poised to replace the cyclosporine class of drugs, these new drugs have the promise of being just as effective while avoiding the major side effects and toxicities associated with cyclosporine. Larsen and Pearson helped drive discovery and development of the co-stimulation blocker belatacept, approved in June 2011 by the U.S. Food and Drug Administration for kidney transplant recipients—the first time a new class of drug had been approved for transplant since the 1990s.

In 2012 Larsen received a new NIH grant for nearly $20 million to lead a research team continuing development of more effective co-stimulation blockers for near-term treatment of transplant patients and better strategies for the "holy grail" of transplantation—long-term, true immune tolerance of transplanted organs.

Larsen has been funded continuously by the NIH since 1996. The recipient of a prestigious NIH MERIT award, he has directed program project grants, center awards, and multi-institutional consortia funded by the NIH and Juvenile Diabetes Research Foundation.

After receiving his bachelor of arts degree in chemistry from Emory College, Larsen received his medical degree from Emory University School of Medicine in 1984. He was a Livingston Surgical Research Fellow at the University of Oxford, England, and he received his doctor of philosophy in transplantation immunology from Oxford in 1990. He completed general and transplantation surgery training at Stanford University and at Emory, where he was chief surgical resident and a fellow in transplantation surgery.

Other notable recognitions include: the 2007 Thomas E. Starzl Prize in Surgery and Immunology, induction to the Institute of Medicine in 2014, the 2021 American Medical Associatoin Scientific Achievement Award, a 2025 Pioneer Award from the American Society of Transplant Surgeons and multiple teaching, lecture and investigator awards from Emory Univeristy.